Canaccord Genuity analyst John Newman maintained a Buy rating on Seres Therapeutics (MCRB) yesterday and set a price target of $11.00. The company’s shares closed last Wednesday at $4.07.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 17.3% and a 44.7% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Atara Biotherapeutics, and Allogene Therapeutics.
Currently, the analyst consensus on Seres Therapeutics is a Strong Buy with an average price target of $8.50, which is an 113.6% upside from current levels. In a report issued on July 28, Oppenheimer also maintained a Buy rating on the stock with a $7.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.75 and a one-year low of $2.15. Currently, Seres Therapeutics has an average volume of 653.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Read More on MCRB:
